

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Harukazu FUKAMI et al) Group Art Unit: To be assigned
Application No.: To be assigned) Prior Examiner: To be assigned
Filed: February 20, 2001)
For: DESCRIPTION QUINAZOLINE)
DERIVATIVES AND)
PHARMACEUTICAL APPLICATIONS)
THEREOF)

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By:


Donna M. Meuth

Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: February 20, 2001

Patent
Attorney's Docket No. 001560-390

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	
)	
Harukazu FUKAMI et al)	Group Art Unit: To be assigned
)	
Application No.: To be assigned)	Prior Examiner: To be assigned
)	
Filed: February 20, 2001)	
)	
For: DESCRIPTION QUINAZOLINE)	
DERIVATIVES AND)	
PHARMACEUTICAL)	
APPLICATIONS THEREOF)	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The references were cited during the PCT international phase. A copy of the International Search Report is also enclosed.


The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

Information Disclosure Statement
Application No. To be assigned
Attorney's Docket No. 001560-390
Page 2

To assist the Examiner, the references are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Donna M. Meuth
Registration No. 36,607

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: February 20, 2001

09/763213

Rec'd PCT/PTO 20 FEB 2001

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION PTO-1449				ATTORNEY'S DKT NO. 001560-390		APPLICATION NO. To be assigned	
				APPLICANT Harukazu FUKAMI et al			
				FILING DATE February 20, 2001		GROUP To be assigned	
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	0 795 548	09/17/97	EP				
	97/45400	12/04/97	WO				
	05 169832	07/09/93	JP			Abstract Only	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Y. Liao, et al., "The chymase-angiotensin system in humans: Biochemistry, molecular biology and potential role in cardiovascular diseases", Canadian Journal of Cardiology, Vol. 11, No. Suppl. F., pages 13F-19F.						
	S. Niwata et al., "Substituted 3-(Phenylsulfonyl)-1-phenylimidazolidine-2,4-dione Derivatives as Novel Nonpeptide Inhibitors of Human Heart Chymase", Journal of Medicinal Chemistry, Vol. 40, No. 14, 1997, pages 2156-2163.						
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.